Inhibikase Therapeutics, Inc. (IKT) is reported to have 14,653,994 shares of common stock beneficially owned for Section 13(d) purposes by reporting persons including RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky, and Rajeev Shah, who expressly disclaim status as a group.
The Fund directly holds 6,970,000 shares of common stock and Pre-Funded Warrants exercisable for up to 18,030,000 shares, subject to a Beneficial Ownership Blocker that limits ownership to 9.99% of outstanding common stock. The Fund is currently prohibited from exercising the Pre-Funded Warrants to the extent such exercise would result in beneficial ownership of more than 7,683,994 shares of common stock.
The ownership percentage is based on 132,032,636 shares outstanding as of May 1, 2026, plus 25,000,000 shares issued to the Fund on July 10, 2026, less 18,030,000 shares surrendered in exchange for Pre-Funded Warrants on July 29, 2026, and giving effect to warrants exercisable within 60 days. Due to EDGAR field limits, Row 11 shows 9.9%. Voting and dispositive power over the securities is shared among the reporting persons, and several of them disclaim beneficial ownership beyond determining their Section 13(d) obligations.
Positive
None.
Negative
None.
Key Figures
Beneficially owned shares:14,653,994 sharesDirect common shares held by Fund:6,970,000 sharesPre-Funded Warrant shares:18,030,000 shares+5 more
8 metrics
Beneficially owned shares14,653,994 sharesAggregate common stock beneficially owned by each reporting person for Section 13(d) purposes
Direct common shares held by Fund6,970,000 sharesShares of Inhibikase common stock directly held by RA Capital Healthcare Fund, L.P.
Pre-Funded Warrant shares18,030,000 sharesMaximum number of Inhibikase common shares issuable upon exercise of the Fund’s Pre-Funded Warrants
Ownership cap9.99%Beneficial Ownership Blocker threshold limiting Fund and affiliates’ ownership
Shares outstanding baseline132,032,636 sharesInhibikase common stock outstanding as of May 1, 2026 used in percentage calculation
Shares issued to Fund25,000,000 sharesCommon shares issued to the Fund in an at-the-market offering on July 10, 2026
Shares surrendered for warrants18,030,000 sharesCommon shares surrendered to Inhibikase in exchange for Pre-Funded Warrants on July 29, 2026
Current warrant exercise limit7,683,994 sharesMaximum common shares the Fund can beneficially own considering the Beneficial Ownership Blocker
Key Terms
Pre-Funded Warrants, Beneficial Ownership Blocker, Section 13(d) of the Act, at-the-market offering, +1 more
5 terms
Pre-Funded Warrantsfinancial
"The Fund directly holds 6,970,000 shares of common stock and pre-funded warrants ("Pre-Funded Warrants")"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Beneficial Ownership Blockerfinancial
"The Pre-Funded Warrants contain a provision (the "Beneficial Ownership Blocker")"
A beneficial ownership blocker is a legal or structural device that prevents a shareholder from being treated as the ultimate owner of enough shares to trigger control, reporting, or voting thresholds. Think of it like a speed bump that stops an investor from reaching a stake size that would force corporate disclosure or change control rights. Investors care because it affects who controls the company, how shares vote, regulatory filings, takeover risk and therefore potential value or liquidity of their holdings.
Section 13(d) of the Actregulatory
"may be deemed a beneficial owner, for purposes of Section 13(d) of the Act"
at-the-market offeringfinancial
"25,000,000 shares of common stock issued to the Fund by the Issuer pursuant to an at-the-market offering"
An at-the-market offering is a method companies use to sell new shares of stock directly into the open market over time, rather than all at once. This allows them to raise money gradually, similar to selling small pieces of a product instead of a large batch. For investors, it means the company can access funding more flexibly, but it may also increase the supply of shares and influence the stock’s price.
beneficial ownershipfinancial
"Row 9 of each Reporting Person's cover page ... sets forth the aggregate number of shares ... beneficially owned"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
What ownership stake in Inhibikase Therapeutics (IKT) is reported by RA Capital and related parties?
The reporting persons disclose beneficial ownership of 14,653,994 shares of Inhibikase common stock, representing 9.99% of the outstanding class for Section 13(d) reporting purposes.
How many Inhibikase (IKT) shares and warrants are held by RA Capital Healthcare Fund, L.P.?
RA Capital Healthcare Fund directly holds 6,970,000 shares of Inhibikase common stock and Pre-Funded Warrants exercisable for up to 18,030,000 shares of common stock, subject to a Beneficial Ownership Blocker.
What is the Beneficial Ownership Blocker described for Inhibikase (IKT) Pre-Funded Warrants?
The Beneficial Ownership Blocker in the Pre-Funded Warrants prevents exercises that would cause the Fund and its affiliates to own more than 9.99% of Inhibikase’s outstanding common stock.
Why is the reported Inhibikase (IKT) ownership percentage shown as 9.9% on the cover pages?
While the narrative explains a 9.99% ownership cap for each reporting person, EDGAR field limitations required rounding down, so Row 11 of each cover page lists the percentage as 9.9%.
What share count did the Inhibikase (IKT) ownership calculation use as a baseline?
The ownership calculation uses 132,032,636 shares of common stock outstanding as of May 1, 2026, plus subsequent issuances and exchanges involving 25,000,000 issued shares and 18,030,000 surrendered shares.
Do the RA Capital reporting persons act as a group in holding Inhibikase (IKT) shares?
The filing states that RA Capital, the Fund, Peter Kolchinsky, and Rajeev Shah are "Reporting Persons" but expressly disclaim status as a "group" for purposes of this Schedule 13G/A amendment.
How much voting and dispositive power do the reporting persons have over Inhibikase (IKT) shares?
The cover pages report 0 sole voting and dispositive power and 14,653,994 shares of shared voting and dispositive power for each reporting person over Inhibikase common stock.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Inhibikase Therapeutics, Inc.
(Name of Issuer)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
45719W205
(CUSIP Number)
07/29/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
45719W205
1
Names of Reporting Persons
RA Capital Management, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
14,653,994.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
14,653,994.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
14,653,994.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
CUSIP Number(s):
45719W205
1
Names of Reporting Persons
Peter Kolchinsky
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
14,653,994.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
14,653,994.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
14,653,994.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
CUSIP Number(s):
45719W205
1
Names of Reporting Persons
Rajeev Shah
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
14,653,994.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
14,653,994.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
14,653,994.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
CUSIP Number(s):
45719W205
1
Names of Reporting Persons
RA Capital Healthcare Fund, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
14,653,994.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
14,653,994.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
14,653,994.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Inhibikase Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
1000 N. West Street, Suite 1200, Wilmington, DE, 19801.
Item 2.
(a)
Name of person filing:
The names of the persons filing this report (collectively, the "Reporting Persons") are:
RA Capital Management, L.P. ("RA Capital")
Peter Kolchinsky ("Dr. Kolchinsky")
Rajeev Shah ("Mr. Shah")
RA Capital Healthcare Fund, L.P. (the "Fund")
The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G/A.
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of each of the Reporting Persons is:
c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116
(c)
Citizenship:
RA Capital and the Fund are Delaware limited partnerships.
Dr. Kolchinsky and Mr. Shah are United States citizens.
(d)
Title of class of securities:
Common Stock, $0.001 par value per share
(e)
CUSIP No.:
45719W205
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.
The Fund directly holds 6,970,000 shares of common stock and pre-funded warrants ("Pre-Funded Warrants") exercisable for up to 18,030,000 shares of common stock. The Pre-Funded Warrants contain a provision (the "Beneficial Ownership Blocker"), which precludes the exercise of the Pre-Funded Warrants to the extent that, following exercise, the Fund, together with its affiliates and other attribution parties, would own more than 9.99% of the common stock outstanding. The Fund is currently prohibited from exercising the Pre-Funded Warrants to the extent that such exercise would result in beneficial ownership of more than 7,683,994 shares of common stock.
RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Act, of any securities of the Issuer held by the Fund. The Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund's portfolio, including the shares of the Issuer's common stock reported herein. Because the Fund has divested voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days' notice, the Fund disclaims beneficial ownership of the securities it holds for purposes of Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Schedule 13G/A other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of this Schedule 13G/A shall not be deemed an admission that either RA Capital, Dr. Kolchinsky, or Mr. Shah is the beneficial owner of such securities for any other purpose.
(b)
Percent of class:
Due to the Beneficial Ownership Blocker listed in the Pre-Funded Warrants, each Reporting Person's beneficial ownership percentage is 9.99%. Such percentage is based upon the sum of (i) 132,032,636 shares of common stock outstanding as of May 1, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on May 12, 2026 and (ii) 25,000,000 shares of common stock issued to the Fund by the Issuer pursuant to an at-the-market offering by the Issuer on July 10, 2026, less the 18,030,000 shares of common stock surrendered to the Issuer by the Fund in exchange for Pre-Funded Warrants on July 29, 2026, and giving effect to Pre-Funded Warrants to the extent exercisable within 60 days hereof, as referenced herein. Due to field limitations of the EDGAR filing system, the percentages listed in Row 11 of the Reporting Persons' cover pages have been rounded down to 9.9%.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.
(ii) Shared power to vote or to direct the vote:
Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.
(iii) Sole power to dispose or to direct the disposition of:
Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.
(iv) Shared power to dispose or to direct the disposition of:
Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
RA Capital Management, L.P.
Signature:
/s/ Peter Kolchinsky
Name/Title:
By Peter Kolchinsky, Authorized Signatory
Date:
07/31/2026
Peter Kolchinsky
Signature:
/s/ Peter Kolchinsky
Name/Title:
Peter Kolchinsky
Date:
07/31/2026
Rajeev Shah
Signature:
/s/ Rajeev Shah
Name/Title:
Rajeev Shah
Date:
07/31/2026
RA Capital Healthcare Fund, L.P.
Signature:
/s/ Peter Kolchinsky
Name/Title:
By RA Capital Healthcare Fund GP, LLC, its General Partner, By Peter Kolchinsky, Manager
Date:
07/31/2026
Exhibit Information
Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Reporting Persons' Schedule 13G filed with the SEC on July 17, 2026).
